Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Janux Therapeutics, Inc. (JANX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights • Initial clinical data from the Phase 1 healthy-volunteer study of JANX011 to be presented during an investor webcast on November 9, 2026 • First patient dosed in the Phase 1 stu
How this was made
The 30-second read
Why it matters
The 8‑K provides the first public disclosure of Q3 financials and key clinical milestones, offering traders fresh data to assess cash runway and upcoming trial readouts.
Market read
Quarterly results and upcoming data release create a short‑term trading catalyst for JANX, with potential volatility around the Nov 9 webcast.
What to watch
The Phase 1 healthy‑volunteer data for JANX011 and the combination study with JANX013 could unlock a broader pipeline, which is not fully priced in yet.
Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Third-quarter net loss, research and development expense, and general and administrative expense were lower than the comparable 2025 period, while Janux reported $945.7 million in cash, cash equivalents and short-term investments and advanced multiple clinical programs. Collaboration revenue and total other income were lower year over year, and the company provided no financial guidance.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Collaboration revenue, three months ended September 30GAAP | $9.29M | – | – |
| Research and development expense, three months ended September 30GAAP | $30.57M | – | – |
| General and administrative expense, three months ended September 30GAAP | $9.98M | – | – |
| Total operating expenses, three months ended September 30GAAP | $40.55M | – | – |
| Loss from operations, three months ended September 30GAAP | −$31.26M | – | – |
| Total other income, three months ended September 30GAAP | $9.69M | – | – |
| Net loss, three months ended September 30GAAP | −$21.57M | – | – |
| Other comprehensive gain (loss), three months ended September 30GAAP | −$4.19M | – | – |
| Comprehensive loss, three months ended September 30GAAP | −$25.76M | – | – |
| Net loss per common share, basic and diluted, three months ended September 30GAAP | $ (0.34) | – | – |
| Weighted-average shares of common stock outstanding, basic and diluted, three months ended September 30GAAP | 63,089,950 | – | – |
| Collaboration revenue, nine months ended September 30GAAP | $23.29M | – | – |
| Research and development expense, nine months ended September 30GAAP | $88.37M | – | – |
| General and administrative expense, nine months ended September 30GAAP | $32.08M | – | – |
| Total operating expenses, nine months ended September 30GAAP | $120.5M | – | – |
| Loss from operations, nine months ended September 30GAAP | −$97.16M | – | – |
| Total other income, nine months ended September 30GAAP | $29.26M | – | – |
| Net loss, nine months ended September 30GAAP | −$67.90M | – | – |
| Other comprehensive gain (loss), nine months ended September 30GAAP | −$10.81M | – | – |
| Comprehensive loss, nine months ended September 30GAAP | −$78.71M | – | – |
| Net loss per common share, basic and diluted, nine months ended September 30GAAP | $ (1.08) | – | – |
| Weighted-average shares of common stock outstanding, basic and diluted, nine months ended September 30GAAP | 62,899,208 | – | – |
| Cash and cash equivalents, September 30, 2026GAAP | $41.82M | – | – |
| Short-term investments, September 30, 2026GAAP | 903.9M | – | – |
| Cash and cash equivalents and short-term investments, September 30, 2026other | $945.7M | – | – |
| Total assets, September 30, 2026GAAP | $983.7M | – | – |
| Total liabilities, September 30, 2026GAAP | 72.04M | – | – |
| Total stockholders' equity, September 30, 2026GAAP | 911.6M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
What drove it
- JANX007 continued Phase 1b development in metastatic castration-resistant prostate cancer, including dose optimization and expansion in taxane-naïve patients and an actively enrolling darolutamide combination cohort.
- The first patient was dosed in the Phase 1 study evaluating JANX013 in combination with JANX007 in patients with metastatic castration-resistant prostate cancer.
- JANX014 continued enrollment in its Phase 1 study evaluating safety, pharmacokinetics and preliminary antitumor activity in patients with metastatic castration-resistant prostate cancer.
- JANX011 continued in a Phase 1 healthy-volunteer study, with initial clinical data scheduled for an investor webcast on November 9, 2026.
Concerns
- Janux reported a net loss of $ (21,570) (in thousands) for the three months ended September 30, 2026.
- Collaboration revenue was $ 9,289 (in thousands) for the three months ended September 30, 2026, compared to $ 10,000 (in thousands) for the comparable 2025 period.
- Total other income was $ 9,688 (in thousands) for the three months ended September 30, 2026, compared to $ 10,938 (in thousands) for the comparable 2025 period.
- The company stated that interim clinical-trial results are not necessarily indicative of final results and that outcomes may materially change as enrollment and data review continue.
What to watch
- Initial clinical data from the Phase 1 healthy-volunteer study of JANX011 during the investor webcast on November 9, 2026.
- Additional clinical data from the Phase 1b study of JANX007 expected at a medical congress in the first half of 2027.
- Enrollment and development progress in JANX007 taxane-naïve monotherapy and darolutamide combination cohorts.
- Progress in the Phase 1 studies of JANX013 in combination with JANX007 and JANX014.
Balance sheet and cash flow
- Cash and cash equivalents were $ 41,818 (in thousands) as of September 30, 2026, compared to $ 52,334 (in thousands) as of December 31, 2025.
- Short-term investments were 903,899 (in thousands) as of September 30, 2026, compared to 914,233 (in thousands) as of December 31, 2025.
- Accounts receivable, net were 411 (in thousands) as of September 30, 2026, compared to — as of December 31, 2025.
- Prepaid expenses and other current assets were 13,254 (in thousands) as of September 30, 2026, compared to 9,320 (in thousands) as of December 31, 2025.
- Total current assets were 959,382 (in thousands) as of September 30, 2026, compared to 975,887 (in thousands) as of December 31, 2025.
- Restricted cash was 816 (in thousands) as of September 30, 2026, compared to 816 (in thousands) as of December 31, 2025.
- Property and equipment, net were 2,795 (in thousands) as of September 30, 2026, compared to 3,852 (in thousands) as of December 31, 2025.
- Operating lease right-of-use assets were 16,772 (in thousands) as of September 30, 2026, compared to 18,402 (in thousands) as of December 31, 2025.
- Other long-term assets were 3,890 (in thousands) as of September 30, 2026, compared to 2,608 (in thousands) as of December 31, 2025.
- Accounts payable were $ 4,303 (in thousands) as of September 30, 2026, compared to $ 4,971 (in thousands) as of December 31, 2025.
- Accrued expenses were 20,089 (in thousands) as of September 30, 2026, compared to 17,633 (in thousands) as of December 31, 2025.
- Current portion of deferred revenue was 27,221 (in thousands) as of September 30, 2026, compared to — as of December 31, 2025.
- Current portion of operating lease liabilities were 2,634 (in thousands) as of September 30, 2026, compared to 2,393 (in thousands) as of December 31, 2025.
- Deferred revenue, net of current portion was 50 (in thousands) as of September 30, 2026, compared to — as of December 31, 2025.
- Operating lease liabilities, net of current portion were 17,746 (in thousands) as of September 30, 2026, compared to 19,746 (in thousands) as of December 31, 2025.
Analysis
Janux remained a clinical-stage company during the third quarter, with collaboration revenue of $ 9,289 (in thousands), compared to $ 10,000 (in thousands) in the comparable 2025 quarter. Total operating expenses were $ 40,547 (in thousands), compared to $ 45,251 (in thousands), reflecting research and development expense of $ 30,565 (in thousands) and general and administrative expense of $ 9,982 (in thousands). The resulting net loss was $ (21,570) (in thousands), compared with $ (24,313) (in thousands).
The nine-month results show collaboration revenue of $ 23,289 (in thousands), compared to $ 10,000 (in thousands) in the prior-year period. Total operating expenses were $ 120,450 (in thousands), compared to $ 125,266 (in thousands), while the nine-month net loss was $ (67,903) (in thousands), compared to $ (81,679) (in thousands). Total other income was lower in both the quarter and the nine-month period than in the comparable 2025 periods.
Liquidity remains the principal financial support for the development portfolio. Janux reported $945.7 million in cash, cash equivalents and short-term investments as of September 30, 2026, compared to $966.6 million as of December 31, 2025. The balance sheet also reported total assets of $ 983,655 (in thousands), total liabilities of 72,043 (in thousands), and total stockholders' equity of 911,612 (in thousands). No capital-return activity was reported.
Operationally, the company continued JANX007 Phase 1b development, including taxane-naïve monotherapy and a darolutamide combination cohort. JANX014 continued enrolling patients in its Phase 1 study, JANX011 remained in a Phase 1 healthy-volunteer study, and Janux dosed the first patient in the Phase 1 study of JANX013 in combination with JANX007. The near-term clinical event is the November 9, 2026 investor webcast for initial JANX011 data, followed by expected additional JANX007 Phase 1b data in the first half of 2027.
Janux did not provide financial guidance in the release. The reported period therefore centers on expense discipline relative to the comparable quarter, a substantial cash and investment position, and execution across four clinical programs rather than on a stated financial outlook.
Management, verbatim
During the third quarter, we continued to execute across our clinical portfolio, including dosing the first patient in the Phase 1 study of JANX013 in combination with JANX007.
David Campbell, Ph.D., President and Chief Executive Officer of Janux
We are also preparing to present initial clinical data from JANX011 on November 9. JANX011 was designed to achieve deep B-cell depletion while limiting cytokine release. The upcoming clinical update will provide an initial look at how this differentiated approach translates into humans.
David Campbell, Ph.D., President and Chief Executive Officer of Janux
Not in the filing
stated, not guessed- Financial guidance
- Prior outlook for comparison
- Gross margin
- Operating cash flow
- Free cash flow
- Debt balance
- Income tax expense or tax rate
- Non-GAAP financial measures
- Share repurchases
- Dividends
- Segment revenue disclosures
- Prior-quarter operating-results comparisons
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Janux Therapeutics (NASDAQ: JANX) is a clinical‑stage biopharma focused on novel immunotherapies for cancer and autoimmune diseases.
Ticker impact
Janux Therapeutics filed an 8‑K reporting Q3 2026 results, cash balance, R&D spend and first patient dosing in a Phase 1 study.
likely modest pressure as investors price in the cash burn and await Phase 1 data; upside potential if early data are positive
Quarterly loss and R&D spend are typical for a clinical‑stage biotech; the cash runway is ample, but the market will react to the upcoming data webcast on Nov 9.
Market effects
Highlights continued cash burn in early‑stage biotech; may influence peer valuations in the immunotherapy space.
Limited to US‑listed biotech investors; no broader regional effect.
Minimal global impact; primarily relevant to biotech sector participants.
Counterpoint
Despite cash burn, the sizable cash balance could support accelerated development, making the stock a potential upside play if data exceed expectations.
Key entities
- companyJanux Therapeutics
Clinical‑stage biotech developing TRACTr, TRACIr, and ARM platforms.
